International Journal of Polymeric Materials · مجلد 75 (8) · 835-858
Folate-conjugated chitosan nanoparticles represent a promising advancement in targeted drug delivery, offering enhanced specificity, biocompatibility, and controlled release profiles. Chitosan, a versatile biopolymer, provides a stable platform for nanoparticle synthesis, while folate conjugation enables selective targeting of folate receptors, which are overexpressed in various cancers and inflammatory diseases. This review explores the structural and functional properties of chitosan, mechanisms of folate receptor-mediated endocytosis, and innovative strategies for nanoparticle synthesis and functionalization. The review entails key formulation techniques, including nanoprecipitation, ionic gelation, and spray drying, alongside characterization methods essential for optimizing therapeutic efficacy. The biomedical applications of Folate-conjugated chitosan nanoparticles are highlighted in cancer therapy, gene delivery, and anti-inflammatory treatments, with an emphasis on emerging trends such as CRISPR-based targeting and dual-ligand strategies. This review critically examines the existing challenges and explores future directions, highlighting the promising role of folate-conjugated chitosan nanoparticles in the evolution of precision medicine.
targeted drug deliveryfolate receptorreceptor-mediated endocytosisnanoprecipitation
Italian Journal of Animal Science · مجلد 24 (1) · 1689-1707
This study is the first to explore the effects of dietary supplementation with chitosan nanoparticles (CHNPs) loaded with berberine (B) and curcumin (CR), either individually or in combination, within high-carbohydrate diets (HCD) on growth performance, health status, and immune-inflammatory gene expression in Nile tilapia. A total of 150 healthy Oreochromis niloticus fingerlings (8.21 ± 0.08 g) were randomly assigned to five groups: control (29% carbohydrate), HCD (42% carbohydrate), and three supplemented groups; B-CHNPs (100 mg berberine/kg HCD), CR-CHNPs (100 mg curcumin/kg HCD), and B-CR-CHNPs (100 mg berberine + curcumin (50:50)/kg HCD) for 100 days. The B-CR-CHNPs treatment significantly enhanced growth, feed utilisation, protein efficiency, digestive enzyme activities, blood protein levels, liver function, and lipid metabolism compared to the HCD group (p < 0.05). Dietary supplementation with Berberine and Curcumin effectively reversed the aberrant changes in liver tissues caused by HCD, restoring hepatic morphology to a state closely resembling normal conditions. Additionally, the dietary treatments significantly enhanced antioxidant status by reducing malonaldehyde levels and increasing total antioxidant capacity and superoxide dismutase activity. B-CR-CHNPs treatment effectively restored the suppressed expression of IgM and LZM genes in the liver of HCD-fed fish. In contrast, the elevated hepatic expression of pro-inflammatory genes TNF-α and IL-1β induced by the HCD was significantly reduced, with the greatest reduction observed in the B-CR-CHNPs group. Berberine and Curcumin showed strong binding to antioxidant, immune, and inflammatory targets. Supplementing Nile tilapia diets with 100 mg B-CR-CHNPs improved growth and mitigated HCD-induced liver damage by modulating metabolism, immunity, and redox balance.
Journal of Radiation Research and Applied Sciences · مجلد 18 (2) · 101537-101537
Objective The H1N1 influenza A virus is the leading cause of seasonal flu outbreaks in humans. Even if there are vaccines for it, it still causes devastating outbreaks and a lot of money to lose. This study aimed to investigate the antiviral efficacy of chitosan nanoparticles and/or propolis against the H1N1 virus. Methods Nanoparticles were synthesized and characterized by transmission electron microscope (TEM). Cytotoxicity was assessed using the MTT assay on Vero cells, and antiviral efficacy was evaluated by calculating the median tissue culture infectious dose (TCID 50 ). Results Chitosan nanoparticles, with average diameters of 100–200 nm were successfully integrated with propolis extract forming rounded aggregates with average diameters ranging between 200 and 300 nm. Remarkably, cytotoxic concentrations against Vero cells for chitosan nanoparticles, propolis extract, and a combination of the two were 277.40 ± 14.94, 238.60 ± 12.25, and 440.10 ± 18.17 μg/mL, respectively. These concentrations indicate high cell viability (>90 %) at doses of 50, 50, and 100 μg/mL, respectively. To evaluate their antiviral effectiveness, the TCID 50 ratios of viral suspensions treated with propolis extract and/or chitosan nanoparticles were compared to those of untreated controls. The results showed that the antiviral activity against the H1N1 influenza A virus improved as the concentration of propolis alone or in the mixture increased, whereas chitosan nanoparticles alone did not exhibit antiviral properties. Conclusions The findings shed light on the possible uses of propolis and chitosan as antiviral drugs against the H1N1 influenza A virus, which are novel, safe, and effective.
Toxicology Research · مجلد 14 (3) · tfaf034-tfaf034
Abstract Peptic ulcer is a chronic inflammatory disorder affecting large portion of population with difficulty in treatment. Treatment options include inhibition of gastric acid secretion, histamine inhibitors, eradication of Helicobacter pylori infection and tissue lining protection. These therapeutic options have several side effects, low bioavailability and bio-distribution. To further increase bioavailability, control release, stability, site specific delivery and minimize organoleptic side effects of phytochemical, nano-encapsulation is a suitable strategy. Chitosan is a suitable nano-carrier for drug delivery applications in treating peptic ulcer as it is biodegradable, biocompatible, safe and cost-effective. Therefore, Ficus religiosa (FR) leaf extract was loaded into chitosan NPs by ion gelation method for in vivo anti-ulcerative activity in indomethacin-induced peptic ulcer rats. Results showed that FR extract was successfully loaded into CNPs with 84% encapsulation efficiency while the size of empty CNPs was reported to be 620.3 nm as compared to FR-loaded CNPs 811.5 nm. FR-loaded CNPs showed homogeneous size distribution as well greater physical stability. Furthermore, in vivo studies revealed gastro-protective activity of FR-loaded CNPs in reducing the ulcer index (UI) to 0.51 (71.30% inhibition) while indomethacin only untreated rats showed UI 2.99 and insignificant ulcer inhibition 11.02%. Furthermore, FR-loaded CNPs restored gastric pH, healed rat stomach completely without ulcers or hemorrhagic spot and improved antioxidants and blood profiles compared to plant extract or CNPs. These findings confirmed the effective application of FR extract loaded CNPs as anti-ulcer agents and reinforces the importance of nano-encapsulation in improving drug efficacy.
Abstract: This study aimed to prepare and characterize chitosan nanoparticles encapsulating a nicotinamide derivative (Ni-CS-NP). Additionally, the therapeutic effectiveness, cytotoxicity, selectivity, and immunomodulatory properties of Ni-CS-NP were evaluated in human breast and colon cancer cell lines. Chitosan nanoparticles have shown potential as drug delivery carriers due to their biocompatibility and controlled release properties. Encapsulating a nicotinamide derivative further enhances the therapeutic potential of these nanoparticles. Computational studies were employed to validate the binding interactions, providing crucial insights into the formulation's stability and effectiveness. The primary objective was to assess the cytotoxicity and safety profiles of Ni-CS-NP in human cancer cell lines. Moreover, this study aimed to investigate the specific mechanisms underlying its cytotoxic effects, including its impact on cell cycle progression, apoptosis induction, and immunomodulation. Ni-CS-NP were synthesized using the ionic gelation method and characterized using Fourier-transform infrared spectroscopy (FT-IR), scanning electron microscopy (SEM), transmission electron microscopy (TEM), and thermo gravimetric analysis. The cytotoxicity was evaluated in breast and colon cancer cell lines through the MTT assay. Selectivity indices were calculated to determine the safety profiles. The inhibition of VEGFR-2, induction of apoptosis, cell cycle disruption, and immunomodulatory effects were assessed through molecular assays. Computational analysis demonstrated favorable binding interactions through the Ni-CS-NP complex. The characterization studies confirmed the successful synthesis of Ni-CS-NP with well-defined structural and thermal properties. Ni-CS-NP exhibited remarkable cytotoxicity with a superior safety profile against MCF7 and HCT 116 cell lines showing IC50 values of 2.32 and 2.70 μM, respectively, surpassing sorafenib's efficacy (IC50 = 4.12 and 7.55 μM, respectively). Additionally, Ni-CS-NP effectively inhibited VEGFR-2, induced both early and late apoptosis, and disrupted the cell cycle progression in MCF7 cells. Notably, Ni-CS-NP demonstrated significant immunomodulatory effects by reducing TNF-α and IL-2 levels compared to dexamethasone. The encapsulation of a nicotinamide derivative within chitosan nanoparticles (Ni-CS-NP) through the ionic gelation method proved successful. Ni-CS-NP displayed potent cytotoxicity, superior safety profiles, and promising immunomodulatory effects in human breast cancer cells. These findings highlight the potential of Ni-CS-NP as a novel therapeutic agent for breast cancer treatment, warranting further investigation for clinical applications.
nicotinamide derivativeschitosan nanoparticlesnanocomplexesanticancer drug delivery
Objective. This study aimed to investigate the preparation of patuletin-encapsulated chitosan nanoparticles (PT-CS-NPs) using the ionic gelation method, evaluate their potential as anticancer agents, and invent a new method of differential pulse voltammetric analysis for patuletin (PT). Methods. Computational studies were conducted to assess the affinity of PT for chitosan, confirming a promising interaction. PT-CS-NPs were synthesized based on the computational outputs, resulting in nanoparticles with an angular structure and an average size of 6.168 nm. The cytotoxicity of PT and PT-CS-NP was evaluated in breast and colon cancer cell lines, and selectivity indices were calculated to assess safety profiles. The electrochemical behavior of PT was also investigated using the Britton–Robinson buffer. Results. PT-CS-NP exhibited both potent cytotoxicity and a favorable safety profile, showing the most active and safest pattern of cytotoxicity among the tested compounds. The electrochemical oxidation of PT was observed at 0.531 V vs. Ag/AgCl at pH 4.0.0. The concentration of PT showed a linear relationship with the corresponding peak current over the range of 10.0 x 10 − 9 : 10.0 x 10 − 5 M M, with a minimum limit of detection of 3.4 × 10(−9)M. The proposed method successfully measured PT, with a relative standard deviation below 2%. Conclusion. The preparation of PT-CS-NP via the ionic gelation method resulted in angular nanoparticles with a promising anticancer activity and safety profiles. The electrochemical behavior of PT was characterized, and a reliable method for PT quantification was established.
The excellent therapeutic potential of a variety of phytochemicals in different diseases has been proven by extensive studies throughout history. However, most phytochemicals are characterized by a high molecular weight, poor aqueous solubility, limited gastrointestinal permeability, extensive pre-systemic metabolism, and poor stability in the harsh gastrointestinal milieu. Therefore, loading of these phytochemicals in biodegradable and biocompatible nanoparticles (NPs) might be an effective approach to improve their bioactivity. Different nanocarrier systems have been developed in recent decades to deliver phytochemicals. Among them, NPs based on chitosan (CS) (CS-NPs), a mucoadhesive, non-toxic, and biodegradable polysaccharide, are considered the best nanoplatform for the oral delivery of phytochemicals. This review highlights the oral delivery of natural products, i.e., phytochemicals, encapsulated in NPs prepared from a natural polymer, i.e., CS, for improved bioavailability and bioactivity. The unique properties of CS for oral delivery such as its mucoadhesiveness, non-toxicity, excellent stability in the harsh environment of the GIT, good solubility in slightly acidic and alkaline conditions, and ability to enhance intestinal permeability are discussed first, and then the outcomes of various phytochemical-loaded CS-NPs after oral administration are discussed in detail. Furthermore, different challenges associated with the oral delivery of phytochemicals with CS-NPs and future directions are also discussed.
chitosan nanoparticlesphytochemicalsoral drug deliverybioavailability
Background: The current chemotherapy agents against various forms of leishmaniasis have some problems and side effects, including high toxicity, high cost, and the emergence of resistant strains. Here, we aimed to review the preclinical studies (in vitro and in vivo) on the anti-leishmanial activity of chitosan and chitosan-based particles against Leishmania spp. Methods: This study was conducted based on the 06-PRISMA guidelines and registered in the CAMARADES-NC3Rs Preclinical Systematic Review and Meta-Analysis Facility (SyRF) database. Various English databases such as PubMed, Google Scholar, Web of Science, EBSCO, ScienceDirect, and Scopus were used to find the publications related to the anti-leishmanial effects of chitosan and its derivatives and other pharmaceutical formulations, without a date limitation, to find all the published articles. The keywords included “chitosan”, “chitosan nanoparticles”, “anti-leishmanial”, “Leishmania”, “leishmaniasis”, “cutaneous leishmaniasis”, “visceral leishmaniasis”, “in vitro”, and “in vivo”. The language for data collection were limited to English. Results: Of 2669 papers, 25 papers, including 7 in vitro (28.0%), 7 in vivo (28.0%), and 11 in vitro/in vivo (44.0%) studies conducted up to 2020 met the inclusion criteria for discussion in this systematic review. The most common species of Leishmania used in these studies were L. major (12, 48.0%), L. donovani (7, 28.0%), and L. amazonensis (4, 16.80%). In vivo, the most used animals were BALB/c mice (11, 61.1%) followed by hamsters (6, 33.3%) and Wistar rats (1, 5.5%), respectively. In vitro, the most used Leishmania form was amastigote (8, 44.4%), followed by promastigote (4, 22.2%), and both forms promastigote/amastigote (6, 33.3%). Conclusion: According to the literature, different types of drugs based on chitosan and their derivatives demonstrated considerable in vitro and in vivo anti-leishmanial activity against various Leishmania spp. Based on the findings of this review study, chitosan and its derivatives could be considered as an alternative and complementary source of valuable components against leishmaniasis with a high safety index. Nevertheless, more investigations are required to elaborate on this result, mainly in clinical settings.
International Journal of Applied Pharmaceutics · 15-19
At present, chemotherapy with some drugs such as nitroimidazoes derivatives is the preferred treatment for giardiasis. However, these agents are associated with adverse side effects ranging from nausea to possible genotoxicity. The present investigation was designed to systematically review the in vitro, in vivo, and clinical studies about the efficacy of nanoparticles against giardiasis. The study was carried out based on the 06-PRISMA guideline and registered in the CAMARADES-NC3Rs Preclinical Systematic Review and Meta-analysis Facility (SyRF) database. The search was performed in five English databases, including Scopus, PubMed, Web of Science, EMBASE, and Google Scholar, without time limitation for publications around the world about anti-Giardia effects of all organic and inorganic nanoparticles without date limitation in order to identify all the published articles. The searched words and terms were “Giardiasis”, “Giardia lamblia”, “Giardia intestinalis”, “Giardia duodenalis”, “nanoparticles”, “nanomedicine”, “in vitro”, in vivo”, and “clinical trial”. Out of 312 papers, 10 papers, including 4 in vitro (40.0%), 5 in vivo (50.0%), and 1 in vitro/in vivo (10.0%) up to 2021 met the inclusion criteria for discussion in this systematic review. The most common type of nanoparticles was metal nanoparticles (5 studies, 50.0%) such as silver, gold, etc., followed by organic nanoparticles such as chitosan nanoparticles (4 studies, 40.0%). The results of this review study showed the high efficacy of a wide range of organic and non-organic NPs against giardiasis, indicating that nanoparticles could be considered as an alternative and complementary resource for treating giardiasis, since they have no significant toxicity. However, more studies are required to elucidate this conclusion, especially in clinical systems.
International Journal of Nanomedicine · مجلد Volume 15 · 7861-7875
Purpose: The topically administered drugs through conventional delivery systems have low bioavailability. Henceforth, the present study was designed to prepare and optimize clarithromycin (CTM)-loaded chitosan nanoparticles (CHNPs) to demonstrate the efficacy against microorganisms. Methods: Clarithromycin-loaded chitosan nanoparticles (CTM-CHNPs) were prepared by ionotropic gelation method. The formulation was optimized by box-Behnken design using the formulation variables like CH (A), STPP concentration (B), and stirring speed (C). Their effects were evaluated on the independent variables like particle size (Y 1 ) and entrapment efficiency (Y 2 ). Further, CTM-CHNPs were evaluated for physicochemical parameters, in-vitro drug release, ex-vivo permeation, bioadhesive study, corneal hydration, histopathology, HET-CAM, and antibacterial study. Results: The optimized formulation (CTM-CHNPopt) showed the low particle size (152± 5 nm), which is desirable for ocular delivery. It also showed high encapsulation (70.05%), zeta potential (+35.2 mV), and was found in a spherical shape. The drug release study revealed a sustained drug release profile (82.98± 3.5% in 12 hours) with Korsmeyer peppas kinetic (R 2 =0.996) release model. It showed a 2.7-fold higher corneal permeation than CTM-solution. CHNPs did not exhibit any sign of damage to excised goat cornea, which is confirmed by hydration, histopathology, and HET-CAM test. It exhibited significant ( P < 0.05) higher antibacterial susceptibility than CTM-solution. Conclusion: The finding of the study concluded that CTM-CHNPs can be used for effective management of bacterial conjunctivitis by increasing the precorneal residence time. Keywords: clarithromycin, chitosan, optimization, nanoparticles, HET-CAM, antimicrobial assessment
clarithromycinchitosan nanoparticlesocular drug deliveryionic gelation
International Journal of Nanomedicine · مجلد Volume 15 · 4717-4737
PURPOSE: The present study was designed to study the gentamycin (GTM)-loaded stimulus-responsive chitosan nanoparticles to treat bacterial conjunctivitis. METHODS: GTM-loaded chitosan nanoparticles (GTM-CHNPs) were prepared by ionotropic gelation method and further optimized by 3-factor and 3-level Box-Behnken design. Chitosan (A), sodium tripolyphosphate (B), and stirring speed (C) were selected as independent variables. Their effects were observed on particle size (PS as Y1), entrapment efficiency (EE as Y2), and loading capacity (LC as Y3). RESULTS: The optimized formulation showed the particle size, entrapment efficiency, and loading capacity of 135.2±3.24 nm, 60.18±1.65%, and 34.19±1.17%, respectively. The optimized gentamycin-loaded chitosan nanoparticle (GTM-CHNPopt) was further converted to the stimulus-responsive sol-gel system (using pH-sensitive carbopol 974P). GTM-CHNPopt sol-gel (NSG5) exhibited good gelling strength and sustained release (58.99±1.28% in 12h). The corneal hydration and histopathology of excised goat cornea revealed safe to the cornea. It also exhibited significant (p<0.05) higher ZOI than the marketed eye drop. CONCLUSION: The finding suggests that GTM-CHNP-based sol-gel is suitable for ocular delivery to enhance the corneal contact time and improved patient compliance.